Brian Freed
Chief Scientific Officer RheumaGen
Dr. Brian Freed leads RheumaGen’s R&D. He is Professor of Medicine and Immunology at the University of Colorado School of Medicine, Anschutz Medical Campus, and he is Founder and Executive Director of CU Anschutz’s ClinImmune, one of the largest nonprofit clinical laboratories in the U.S. ClinImmune has generated over $200M in clinical revenue. Dr. Freed is the lead inventor of RheumaGen’s breakthrough HLA gene-editing therapies. He is a world-class expert in the HLA gene, with over 40 years of experience and more than 100 publications in the areas of immunogenetics, biotherapeutics, histocompatibility, transplantation, and stem-cell banking.
Seminars
Thursday 5th March 2026
Advancing Gene-Edited Cell Therapies in Rheumatoid Arthritis: Streamlined Clinical Development for Multi-Indication Translation
2:30 pm
- Highlighting a platform-centric gene editing strategy that harmonizes clinical protocols and manufacturing processes, allowing a single target modification to be applied across multiple autoimmune indications
- Showcasing a multi-indication clinical development pathway that leverages Phase I safety and mechanistic insights to accelerate Phase II expansion, streamlining translation across diverse disease contexts
NEW DATA
